31 results about "Isoindoles" patented technology

This invention relates to the compound (2R)-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4 -yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-[(1S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl]propanamide, and in particular to novel physical forms of the compound, a process for preparing the compound and synthetic intermediates for use in the process, and novel formulations containing the compound, as well as therapeutic uses of the compound.

The invention belongs to the technical field of medicine synthesis processes, and particularly relates to a preparation method of high-yield and high-purity tandospirone citrate. According to the method, pyrimido piperazine quaternary ammonium salt and isoindoledione are used as raw materials, a toluene and n-butanol and / or n-amyl alcohol mixed solvent is used as a solvent, tandospirone can be generated under the alkaline condition without adding a phase transfer catalyst, after acid adjustment extraction and specific organic solvent reverse phase impurity removal, a water phase is adjusted to be alkaline, and the tandospirone is obtained. And extracting with toluene, and adding a citric acid ethanol solution to directly separate out a citric acid tandospirone solid. The preparation process disclosed by the invention has a very good impurity removal effect, and the obtained tandospirone citrate is high in purity, high in process yield, good in atom economy and low in output of three wastes.

The invention relates to a compound of formula (I) wherein n = 1 or 2, A and A'are independently selected from the group consisting of the following substituents (II-a) and (II-b), R and R 'are independently selected from H and a linear or branched C1-C3 alkyl group, Z is selected from a linear or branched C1-C4 alkyl group and an aryl group optionally substituted by a linear or branched C1-C3 alkyl group and / or by a hydroxyl group, and the structural unit of formula (N) is selected from the following structural units (III-a), (III-b), (III-c), (III-d) and (III-e) wherein for each structural unit (III-a), (III-b), (III-c), (III-d) and (III-e), Ra, Rb, Rc and Rd are independently selected from a linear or branched C1-C4 alkyl group. .

According to the boron-containing fused ring compound based on 2H-isoindole and the organic electroluminescent device thereof, boron is contained, a large pi conjugated group is adopted as a parent structure, separation of HOMO and LUMO is achieved through the resonance effect of boron atoms and nitrogen atoms, the multiple resonance thermal activation delayed fluorescence effect is generated, most of the molecular skeletons of the compound are six-membered rings, and the molecular skeletons of the compound are different. The skeleton structure of the fused ring compound provided by the invention contains 2H-isoindole with a five-membered ring structure, so that the material molecules have asymmetry, the SOC is increased, the anti-intersystem transition rate is increased, the EST is reduced, the skeleton system of the MR-TADF material is enriched, and meanwhile, different substituent groups are introduced into the rigid skeleton, so that the molecular weight of the MR-TADF material is increased. Further adjustment on the delayed fluorescence lifetime and the half-peak width is realized. A B-N polar bond of the compound is doped into an MR resonance skeleton to serve as a luminescent material, the luminescent material has remarkable advantages in the aspect of photoelectric properties, and when the luminescent material serves as a luminescent material in an OLED device, the luminescent material has the remarkable advantages of regulating light color, improving quantum yield and prolonging the service life of the device.

A 1,6-diynes compound, its preparation method, and products obtained from 1,6-diynes as raw material and their applications are disclosed, belonging to the field of organic synthesis. The compound represented by a general formula (I), and its tautomers, polymorphs, solvates, or salts thereof, The 1,6-diyne compounds provided in the present application have variable structures, are easy to be synthesized, and are suitable for industrial production; they can be used for the synthesis of a class of benzoisoindole dimer compounds and their derivatives, cell imaging, and detecting reactive oxygen species (such as sodium hypochlorite, hydrogen peroxide, ozone, etc.). The 3-arylbenzoisoindole compound provided in the present application can be used as an important compound and play an important role in pharmaceuticals or fluorescent materials.

To provide pharmaceutical compositions for treating solid tumor, in particular, glioblastoma multiforme (GBM).SOLUTION: Provided herein is a pharmaceutical composition for use in a method for retarding progression of brain tumor, where the composition comprises a therapeutical effective dose of F16, that is, isoindole (1, 3-dioxy-2, 3-dihydro-1H-isoindol-4-yl)-amide and a therapeutically effective dose of a chemotherapeutic agent in a pharmaceutical carrier, where the brain tumor is glioblastoma multiforme, and the chemotherapeutic agent is temozolomide (TMZ) or bevacizumab (BVZ) or similar agent.SELECTED DRAWING: Figure 1

The invention belongs to the field of synthesis of lithium ion battery positive electrode materials, and relates to a cobalt-based coordination polymer material and a preparation method and application thereof, wherein the preparation steps are as follows: 2,7-(1,2,4-tetrazolyl)benzophenanthroline tetraketone (4-DTBPT) is ultrasonically dissolved in an appropriate amount of organic solvent, and then an appropriate amount of distilled water and isoindolediacetic acid (BGPD) are added, and after being fully dissolved, all are transferred to an autoclave, an appropriate amount of cobalt salt is weighed and placed in the autoclave, and a reaction is carried out in an oven, and after cooling, pink strip crystals are obtained by filtering. The molecular formula of the crystals is C 52 H 38 CoN 18 O 20 (Co‑CP). It has broad application prospects in the field of lithium-ion battery electrode materials. The synthesis method of the present invention is simple, easy to produce, low in cost, and has good reproducibility. It is a new inorganic-organic hybrid electrode material and has broad application prospects in the fields of energy storage systems such as lithium batteries and wearable devices.

The invention discloses flame-retardant epoxy resin as well as a preparation method and application thereof. The flame-retardant epoxy resin provided by the invention is co-crosslinked flame-retardant epoxy resin containing cyclotriphosphazene and nitrogen heteroaromatic ring, and the nitrogen heteroaromatic ring comprises at least one of an isoindole ring, a triazine ring and a phthalocyanine ring. The flame-retardant epoxy resin is realized by introducing a branched nitrile resin containing cyclotriphosphazene and a para-ammonia structure into epoxy resin. The flame retardant property of the flame-retardant epoxy resin is effectively improved through the synergistic flame retardant effect formed by the cyclotriphosphazene and the nitrogen-containing heteroaromatic ring structure.

A 1,6-diynes compound, its preparation method, and products obtained from 1,6-diynes as raw material and their applications are provided. The compound represented by a general formula (I), and its tautomers, polymorphs, solvates, or salts thereof,The 1,6-diyne compounds provided have variable structures, are easy to be synthesized, and are suitable for industrial production; they can be used for the synthesis of a class of benzoisoindole dimer compounds and their derivatives, cell imaging, and detecting reactive oxygen species (such as sodium hypochlorite, hydrogen peroxide, ozone, etc.). The 3-arylbenzoisoindole compound provided can be used as an important compound and play an important role in pharmaceuticals or fluorescent materials.

The invention provides a method for preparing a mitiglinide calcium intermediate. The method comprises the following steps: S-benzylsuccinic acid, a condensing agent, cis-perhydroisoindole or a salt thereof, and benzyl alcohol are reacted in one step to generate mitiglinide benzyl ester. The reaction method has high yield, low cost, simple operation, safety, environmental protection, and is suitable for large-scale industrial production.

The application discloses synthesis of EGFR inhibitors and purposes thereof, and belongs to the technical field of medicines. The application relates to synthesis of a class of oxoisoindole compounds and pharmaceutically acceptable salts of the oxoisoindole compounds and purposes thereof. The compounds or the salts thereof can selectively inhibit EGFR, and thus can be used for treating or improving abnormal cell proliferation diseases.

The present invention discloses a preparation process of N-Bn-3A,4,7,7A-tetrahydroisoindole. The preparation process route is as follows: The starting reactant is tetrahydrophthalic anhydride, which undergoes a reduction reaction in step (1) to generate compound a, then undergoes a substitution reaction in step (2) to generate compound b, and finally undergoes a ring-closure reaction in step (3) to obtain the target product. The present invention can react in a low-temperature system, with safe operation, reduced cost, convenient treatment, and a high yield.

The invention discloses a benzoxazino isoindolone compound as well as a synthesis method and application thereof, and belongs to the field of organic synthesis. A 2-aryl benzoxazine compound 1 and a fluoro methyl acetylenic ketone compound 2 are used as raw materials, and in the presence of a rhodium catalyst, an additive and an organic solvent, a temperature rise reaction is performed to obtain the benzoxazino isoindolone compound 3. A plurality of groups of compounds are screened, and antiviral and anticancer activity tests verify that the compound provided by the invention has the activity of obviously inhibiting proliferation of three cancer cells such as the Zika virus and Hela, A549 and HCT-116, so that the compound provided by the invention has the activity of resisting the Zika virus and has the anticancer activity on cervical cancer, lung cancer and colon cancer.

Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindo1-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

The present invention provides a new synthetic method for the preparation of building block indole-3-carboxylic acid (ICA) derivatives used as a key starting material to produce several artificial drugs. An efficient, safe, operationally simple, cost-effective method for the preparation of several ICA derivatives has been introduced in a very simple way. Utilizing easily available starting material, reagent, and solvent several key starting materials of ICA derivatives have been synthesized rapidly indicates the novel method is functional group tolerable. The preparation process does not involve use of any reducing agents or transition metals in the economically viable and operationally simple condition in one pot. ICA derivatives have been generated from isatin derivative in one step and this methodology is important with a wide range of applications from the drug development and material synthesis CN point of view.

The invention discloses a preparation method of a crude drug for inhibiting release of platelet factors, which comprises the following steps: 1) reacting 2-[4-(1, 3-dioxo-2-isoindolyl) phenyl] butyric acid with glacial acetic acid, zinc powder and hydrochloric acid at a stirring speed of 120-140 r / min to obtain a wet solid; (2) refining the wet solid product obtained in the step (1) to obtain a medicine crude product for inhibiting the release of the platelet factors; the crude drug product for inhibiting the release of the platelet factors, which is obtained by the invention, has higher purity and yield.

2-(Piperidin-3-yl)isoindole-1,3-dione analogs and uses thereof are disclosed. The compounds have a structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt, solvate, or hydrate thereof. The compounds may be useful for inhibiting TNF-α activity, TNF-α synthesis, interleukin-6 (IL-6) level, inflammation, or SARS-COV-2 virus. In some aspects, the compounds, or pharmaceutical compositions including the compounds, are administered to a subject a traumatic brain injury (TBI), an inflammatory disorder, a neurodegenerative disease, cancer, a viral infection, or any combination thereof.

The present invention relates to a method for treating a tumor such as a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and / or an MEK inhibitor.

The invention provides a method for synthesizing an isoindolo [2, 1-a] pyrrolo [2, 1-c] quinoxaline compound, and relates to the technical field of organic synthesis. The isoindolo [2, 1-a] pyrrolo [2, 1-c] quinoxaline compound is obtained by mixing a compound 1, a compound 2, trifluoromethanesulfonic anhydride and a polar solvent and carrying out cyclization reaction under a protective atmosphere. A one-pot method is adopted for one-step synthesis, the synthesis process is simple, and the product yield is high. According to the method provided by the invention, the preparation raw materials are safe, dangerous reagents such as azide and the like and raw materials such as a metal catalyst and a toxic oxidant which are commonly used in a traditional two-step synthesis route are avoided, potential safety hazards are fundamentally eliminated, and the method conforms to the development trend of green chemistry, has higher operation safety and environmental friendliness, and is suitable for industrial production. The production cost is low. Furthermore, the method provided by the invention is mild in reaction condition, low in energy consumption, short in time consumption and high in production efficiency.

The invention relates to a preparation method of a lenalidomide compound. The process comprises the following steps: in a N-methyl pyrrolidone or acetonitrile solvent, by using triethylamine or DIPEA (Diisopropylethylamine) as an acid binding agent, enabling 2-bromomethyl-3-nitrobenzoate to react with alpha-amino glutarimide hydrochloride, so as to obtain 3-(4-nitro-1-oxo-1, 3-dihydroisoindole-2-yl)-piperidine-2, 6-diketone; in the presence of hydrazine hydrate and Pd / C, nitryl of 3-(4-nitro-1-oxo-1, 3-dihydroisoindole-2-yl)-piperidine-2, 6-diketone is reduced, and lenalidomide is obtained. The process is easy and convenient to operate and mild in reaction condition, the purity of the obtained lenalidomide reaches 99.9% or above, the impurity content is extremely low, and the method is suitable for industrial production. The invention also provides high-purity lenalidomide prepared on the basis of the process and an industrial production method of the lenalidomide.

The invention provides a quinazolinone isoindole derivative as well as a preparation method and application thereof, and belongs to the technical field of organic synthetic chemistry. The preparation method of the quinazolinone isoindole derivative comprises the following steps: adding a quinazolinone compound 1, an alkyne compound 2, an additive and a catalyst into a solvent, and reacting to obtain the quinazolinone isoindole derivative. The invention provides a simple and effective method for synthesizing a highly functionalized heterocyclic ring and realizing a new framework compound taking alkyne as a single carbon unit, and the method has the characteristics of mild reaction conditions, simple operation, economical steps, strong functional group tolerance, excellent yield and the like. The quinazolinone isoindole derivative has a good antibacterial effect on rhizoctonia solani, tobacco shin black fungus, fusarium graminearum, fusarium oxysporum, fusarium moniliforme, peanut sclerotium rolfsii, wheat take-all and wheat sheath blight. The sterilization rate of the compound 3al on rhizoctonia solani can reach 85.18%, and the compound 3al has a certain application prospect.

Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2 (1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

The invention relates to the technical field of solar cell preparation, in particular to a benzisoindole compound with a conjugated polycyclic structure and application of the benzisoindole compound. The structural general formula of the compound is as shown in formula I, wherein R1 is benzene ring, thiophene, furan, pyridine, 2-phenyl thiophene, 2-phenyl furan and / or biphenyl, bithiophene and bifuran substituent, and R2 is benzene ring and / or hydrogen. In conclusion, the invention provides a novel material system with high efficiency, high stability and low cost for the exciton splitting type photovoltaic cell, which is hopeful to accelerate breakthrough of the limit of the Porcley-Quinisseria theory and promote the practical development of the third generation solar cell technology.

The application discloses a preparation method of lenalidomide, which comprises the following steps: S1, methyl 2-bromomethyl-3-nitrobenzoate, 3-aminopiperidine-2,6-dione hydrochloride and a base are dissolved in a polar solvent, and reaction is carried out at 50-60 DEG C for 5-8 h; after the reaction is completed, the obtained mixed product is refined and purified to obtain 3-(7-nitro-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; S2, 3-(7-nitro-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione, ammonium formate and a palladium-carbon catalyst are added into a mixed solvent, and reaction is carried out at 35-45 DEG C for 4-7 h; after the reaction is completed, the obtained crude product is further treated; S3, the crude product is stirred and dissolved in a polar solvent, and then filtered; ammonium formate and sodium mercaptoacetate are added into the filtrate, and reaction is carried out under stirring for 2-5 h; after the reaction is completed, the obtained mixed solution is refined and purified to obtain lenalidomide.

A method for electrochemically driving 2-(1-alkynyl)benzamide derivative to cyclize and synthesize iodoisoindolone, in which 2-(1-alkynyl)benzamide derivative and tetrabutylammonium iodide are used in an electrolyte and a solvent at room temperature to obtain iodoisoindolone. The electrochemical driving efficiency is higher, the substrate conversion rate is increased to 95%, heavy metal residues are avoided, the requirements of drug intermediates are met, no temperature control energy consumption is needed, the process is simplified, the efficiency is improved, and the functional group tolerance is better.

The application discloses application of a benzimidazole amine derivative in preparation of an antitumor pharmaceutical composition, in particular, application of a benz(4,5)imidazo(2,1-a)isoindole-2-methylprop-2-amine derivative in preparation of an antitumor pharmaceutical composition. The benz(4,5)imidazo(2,1-a)isoindole-2-methylprop-2-amine derivative provided by the application has a significant inhibiting effect on colon cancer, liver cancer, lung cancer, prostate cancer, cervical cancer, neuroglioma and breast cancer, shows excellent antitumor characteristics, can be used as a leading drug molecule for resisting tumors, and has a good development and application prospect in development of antitumor drugs.

The invention belongs to the field of organic synthesis, and particularly relates to a synthesis method of isoindolone. N-methylbenzylamine derivative as shown in formula 1, N-methyl-N-(4-pyridylmethyl) amine as shown in formula 4, N-methyl-2-thiophenemethylamine as shown in formula 6, 2-methoxy methyl benzoate derivative as shown in formula 2 and 2-methoxy methyl nicotinate pyridine as shown in formula 9 in bis (trimethylsilyl) The method comprises the following steps of: mixing and reacting with an organic solvent methyl tert-butyl ether in the presence of a catalyst, lithium amide and a cesium fluoride additive to synthesize isoindolone as shown in a formula 3, isoindolone as shown in a formula 5, isoindolone as shown in a formula 7 and isoindolone as shown in a formula 10.

The invention discloses an N-cyclopropyl isoindole compound as well as a preparation method and application thereof, and relates to an N-cyclopropyl isoindole compound shown in a structure of a claimed formula I as well as a preparation method and pharmaceutical application of the N-cyclopropyl isoindole compound. The N-cyclopropyl isoindole compound provided by the invention not only has good inhibitory activity on a sigma-2 receptor, but also shows high selectivity on the sigma-2 receptor. Therefore, the N-cyclopropyl isoindole compound provided by the invention has a prospect of being developed into drugs for treating diseases which are prevented, treated or relieved by inhibiting the sigma-2 receptor, and the diseases which are prevented, treated or relieved by inhibiting the sigma-2 receptor comprise nervous system diseases and tumors, such as nervous system diseases and tumors. The nervous system diseases comprise Alzheimer's disease, schizophrenia and dementia with Lewy bodies. # imgabs0 #

The invention provides an application of 4-bromo-N-(1-methyl-3-(4-methylbenzoyl)-2H-isoindole-2-yl) benzenesulfonamide in preparation of an antitumor drug, and relates to the technical field of biomedicine. The invention provides an excellent potential of 4-bromo-N-(1-methyl-3-(4-methylbenzoyl)-2H-isoindoline-2-yl) benzenesulfonamide (ISO-1 for short) in the aspect of resisting colon cancer, and a cell experiment carried out by a CCK-8 method in the application shows that the ISO-1 has a direct killing effect on colon cancer MC38 cells. In a mouse colon cancer model constructed by MC38 cells, the treatment effect of the ISO-1 is further confirmed. Experimental results show that compared with an untreated Control group, the tumor volume of each group of mice treated by ISO-1 is obviously reduced. The ISO-1 treatment obviously prolongs the lifetime of tumor-bearing mice. The lifetime is one of gold standards for measuring the effectiveness of anti-cancer drugs.